Recap: Ascendis Pharma Q3 Earnings
Portfolio Pulse from Benzinga Insights
Ascendis Pharma (NASDAQ:ASND) reported Q3 earnings, missing estimated earnings by 13.82% with an EPS of $-3.13 versus an estimate of $-2.75. However, revenue was up $36.87 million from the same period last year. Last quarter, the company beat EPS estimates which led to a 4.24% increase in the share price the next day.
November 07, 2023 | 9:15 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Ascendis Pharma's Q3 earnings missed estimates, which could potentially lead to a short-term decrease in stock price. However, the company's revenue increase and past performance of stock price increase following an EPS beat could mitigate this.
Earnings reports are a significant factor in a company's stock price. Ascendis Pharma's miss on earnings estimates could lead to a decrease in stock price. However, the company's revenue increase and past performance of stock price increase following an EPS beat could offset this negative impact.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100